Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Accepts Actelion's NDA For Macitentan

Actelion Pharmaceuticals Ltd. (ALIOF.PK, ATLN.L) Friday said its New Drug Application, or NDA, for macitentan has been accepted by The U.S. Food and Drug Administration.

Macitentan is registered under the name Opsumit, and is used for the treatment of patients with pulmonary arterial hypertension.

Pulmonary arterial hypertension is a chronic disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual.

In a random, pivotal, long-term Phase III study, Macitentan was found to reduce the risk of morbidity and mortality event over the treatment period versus placebo.

For patients in the 10 mg and 3 mg dose group, risk was reduced by 45 percent and 30 percent, respectively. Meanwhile, nasopharyngitis, headache and anemia were the most common adverse events associated with the use of macitentan.

The review period is expected to last 12 months from the date of NDA submission.

Click here to receive FREE breaking news email alerts for Actelion Ltd., and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Consumer confidence in the U.S. improved for the third consecutive month in July, according to a report released by the Conference Board on Tuesday, with the consumer confidence index jumping to its highest level in almost seven years. Stocks have moved mostly higher in early trading on Tuesday after ending the previous session roughly flat. The major averages have climbed into positive territory, although there does not seem to be much conviction behind the upward move. Home prices in major U.S. metropolitan areas continued to increase at a slower pace in the month of May, Standard & Poor's revealed in a report released on Tuesday. The report said the S&P/Case-Shiller 20-City Composite Home Price Index increased at an annual rate of 9.3 percent in May compared to the 10.8 percent growth reported for April.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.